Analysts Set Urogen Pharma (NASDAQ:URGN) PT at $32.00

Urogen Pharma (NASDAQ:URGN) has received an average recommendation of “Moderate Buy” from the nine brokerages that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $32.00.

A number of analysts recently commented on URGN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a research note on Wednesday, October 8th. Wall Street Zen raised shares of Urogen Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. D. Boral Capital reissued a “buy” rating and issued a $25.00 price objective on shares of Urogen Pharma in a research report on Monday, October 27th. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Urogen Pharma in a research report on Monday, October 27th. Finally, Piper Sandler started coverage on Urogen Pharma in a report on Monday, August 18th. They issued an “overweight” rating and a $36.00 price target for the company.

Urogen Pharma Price Performance

Shares of URGN opened at $29.42 on Friday. Urogen Pharma has a 1-year low of $3.42 and a 1-year high of $30.00. The stock has a market cap of $1.38 billion, a price-to-earnings ratio of -8.50 and a beta of 1.06. The firm has a 50 day simple moving average of $20.44 and a 200-day simple moving average of $16.53.

Urogen Pharma (NASDAQ:URGN) last announced its earnings results on Thursday, November 6th. The company reported ($0.69) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.03. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 170.59%.The firm had revenue of $27.48 million for the quarter, compared to analysts’ expectations of $34.09 million. On average, equities analysts expect that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Insider Activity

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of Urogen Pharma stock in a transaction dated Wednesday, November 19th. The stock was sold at an average price of $25.00, for a total value of $250,000.00. Following the completion of the sale, the insider owned 139,025 shares in the company, valued at $3,475,625. The trade was a 6.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Chris Degnan sold 2,203 shares of Urogen Pharma stock in a transaction dated Wednesday, October 8th. The shares were sold at an average price of $16.85, for a total value of $37,120.55. Following the completion of the sale, the chief financial officer owned 2,280 shares of the company’s stock, valued at $38,418. This trade represents a 49.14% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 14,594 shares of company stock valued at $332,813 over the last quarter. Company insiders own 4.70% of the company’s stock.

Institutional Investors Weigh In On Urogen Pharma

Several hedge funds have recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Urogen Pharma by 216.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company’s stock worth $48,227,000 after purchasing an additional 2,983,368 shares during the last quarter. Paradigm Biocapital Advisors LP acquired a new position in Urogen Pharma in the third quarter valued at $84,111,000. RA Capital Management L.P. purchased a new stake in Urogen Pharma during the first quarter valued at about $35,461,000. Soleus Capital Management L.P. purchased a new stake in Urogen Pharma during the second quarter valued at about $29,934,000. Finally, Vestal Point Capital LP increased its stake in Urogen Pharma by 32.1% during the first quarter. Vestal Point Capital LP now owns 2,152,957 shares of the company’s stock worth $23,812,000 after acquiring an additional 522,957 shares during the last quarter. 91.29% of the stock is owned by institutional investors and hedge funds.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.